Objective:
Report preliminary safety and visual field findings from the first three participants in the ER-100 glaucoma cohort.
Approach:
- Study context: ER-100 is being studied as an epigenetic restoration therapy for optic neuropathies, including glaucoma and nonarteritic anterior ischemic optic neuropathy (NAION).
- Data presented: The report covers the first three glaucoma-cohort participants treated at the lowest ER-100 dose.
Key Findings:
- The three participants were reported to have tolerated ER-100, with no adverse events or dose-limiting toxicities.
- Humphrey visual field testing showed evidence of improvement at a number of points.
Interpretation:
These are preliminary findings from the first three participants in the lowest-dose glaucoma cohort.
Limitations:
- The report includes only three participants.
- The source provides no detailed visual field results, follow-up duration, or comparison group.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.